{"id": "399871", "url": "https://fevir.net/resources/Composition/399871", "date": "2025-12-11T20:35:21.032Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report"], "versionId": "5", "lastUpdated": "2025-12-11T20:35:21.032Z"}, "type": {"text": "Participant Flow Report", "coding": [{"code": "ParticipantFlowReport", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowReport"}]}, "title": "Participant Flow Report for NCT03421379", "author": [{"display": "[No author listed.]"}], "status": "final", "contained": [{"id": "FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"]}, "name": "NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride", "type": "person", "membership": "enumerated", "description": "A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2.", "resourceType": "Group", "characteristic": [{"code": {"text": "Research Study from which this is a flow group"}, "exclude": false, "valueReference": {"display": "NCT03421379"}}]}, {"id": "FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"]}, "name": "NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "type": "person", "membership": "enumerated", "description": "A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2.", "resourceType": "Group", "characteristic": [{"code": {"text": "Research Study from which this is a flow group"}, "exclude": false, "valueReference": {"display": "NCT03421379"}}]}, {"id": "NCT03421379-flow-milestone-0-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 34}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-0-Period-1-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "STARTED at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-0-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 41}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-0-Period-1-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "STARTED at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-1-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 33}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-1-Period-1-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "Received at Least One Dose of Study Drug at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-1-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 39}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-1-Period-1-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "Received at Least One Dose of Study Drug at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-2-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 32}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-2-Period-1-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "COMPLETED at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-2-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 37}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-2-Period-1-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "COMPLETED at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-3-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 2}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-3-Period-1-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "NOT COMPLETED at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-3-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 4}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-3-Period-1-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "NOT COMPLETED at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-reason-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"category": {"text": "Withdrawal by Subject"}, "quantity": {"value": 0}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}, {"category": {"text": "Physician Decision"}, "quantity": {"value": 1}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}, {"category": {"text": "Did not receive treatment"}, "quantity": {"value": 1}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-reason-Period-1-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "Reasons for withdraw at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-reason-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"category": {"text": "Withdrawal by Subject"}, "quantity": {"value": 1}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}, {"category": {"text": "Physician Decision"}, "quantity": {"value": 1}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}, {"category": {"text": "Did not receive treatment"}, "quantity": {"value": 2}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-reason-Period-1-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "Reasons for withdraw at Period 1"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 32}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "STARTED at Washout Period (3 to 14 Days)"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 37}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "STARTED at Washout Period (3 to 14 Days)"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 32}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "COMPLETED at Washout Period (3 to 14 Days)"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 37}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "COMPLETED at Washout Period (3 to 14 Days)"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 0}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "NOT COMPLETED at Washout Period (3 to 14 Days)"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 0}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "NOT COMPLETED at Washout Period (3 to 14 Days)"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-0-Period-2-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 32}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-0-Period-2-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "STARTED at Period 2"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-0-Period-2-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 37}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-0-Period-2-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "STARTED at Period 2"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-1-Period-2-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 32}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-1-Period-2-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "COMPLETED at Period 2"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-1-Period-2-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 37}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-1-Period-2-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "COMPLETED at Period 2"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-2-Period-2-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 0}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-2-Period-2-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "NOT COMPLETED at Period 2"}, "variableRole": "outcome"}]}, {"id": "NCT03421379-flow-milestone-2-Period-2-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 0}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-flow-milestone-2-Period-2-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "NOT COMPLETED at Period 2"}, "variableRole": "outcome"}]}], "custodian": {"type": "Organization", "display": "Computable Publishing LLC", "reference": "Organization/118079"}, "relatesTo": [{"type": "cite-as", "targetMarkdown": "Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json."}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "399871", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-participant-flow-report", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Composition", "section": [{"code": {"text": "FlowPreAssignmentDetails", "coding": [{"code": "participant-flow-details", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Participant Flow Details"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Participants were randomized to receive either nasal glucagon or intramuscular (IM) glucagon in the first period, followed by the alternate treatment in the second period.</div>", "status": "generated"}, "title": "Flow PreAssignment Details"}, {"code": {"text": "FlowGroupList"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Glucagon Nasal Powder/Glucagon Hydrochloride, Glucagon Hydrochloride Solution/Glucagon Nasal Powder</div>", "status": "generated"}, "entry": [{"type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride", "reference": "#FG000"}, {"type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "reference": "#FG001"}], "title": "Flow Group List"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1", "reference": "#NCT03421379-flow-milestone-0-Period-1-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1", "reference": "#NCT03421379-flow-milestone-0-Period-1-group-FG001"}], "focus": {"display": "STARTED at Period 1"}, "title": "STARTED at Period 1"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1", "reference": "#NCT03421379-flow-milestone-1-Period-1-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1", "reference": "#NCT03421379-flow-milestone-1-Period-1-group-FG001"}], "focus": {"display": "Received at Least One Dose of Study Drug at Period 1"}, "title": "Received at Least One Dose of Study Drug at Period 1"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1", "reference": "#NCT03421379-flow-milestone-2-Period-1-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1", "reference": "#NCT03421379-flow-milestone-2-Period-1-group-FG001"}], "focus": {"display": "COMPLETED at Period 1"}, "title": "COMPLETED at Period 1"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1", "reference": "#NCT03421379-flow-milestone-3-Period-1-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1", "reference": "#NCT03421379-flow-milestone-3-Period-1-group-FG001"}], "focus": {"display": "NOT COMPLETED at Period 1"}, "title": "NOT COMPLETED at Period 1"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1", "reference": "#NCT03421379-flow-reason-Period-1-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1", "reference": "#NCT03421379-flow-reason-Period-1-group-FG001"}], "focus": {"display": "Reasons for withdraw at Period 1"}, "title": "Reasons for withdraw at Period 1"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)", "reference": "#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)", "reference": "#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001"}], "focus": {"display": "STARTED at Washout Period (3 to 14 Days)"}, "title": "STARTED at Washout Period (3 to 14 Days)"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)", "reference": "#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)", "reference": "#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001"}], "focus": {"display": "COMPLETED at Washout Period (3 to 14 Days)"}, "title": "COMPLETED at Washout Period (3 to 14 Days)"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)", "reference": "#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)", "reference": "#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001"}], "focus": {"display": "NOT COMPLETED at Washout Period (3 to 14 Days)"}, "title": "NOT COMPLETED at Washout Period (3 to 14 Days)"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2", "reference": "#NCT03421379-flow-milestone-0-Period-2-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2", "reference": "#NCT03421379-flow-milestone-0-Period-2-group-FG001"}], "focus": {"display": "STARTED at Period 2"}, "title": "STARTED at Period 2"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2", "reference": "#NCT03421379-flow-milestone-1-Period-2-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2", "reference": "#NCT03421379-flow-milestone-1-Period-2-group-FG001"}], "focus": {"display": "COMPLETED at Period 2"}, "title": "COMPLETED at Period 2"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2", "reference": "#NCT03421379-flow-milestone-2-Period-2-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2", "reference": "#NCT03421379-flow-milestone-2-Period-2-group-FG001"}], "focus": {"display": "NOT COMPLETED at Period 2"}, "title": "NOT COMPLETED at Period 2"}]}